Park Hye Seok, Lee Sung Ho, Kim Kang Min, Cho Won-Sang, Kang Hyun-Seung, Kim Jeong Eun, Ha Eun Jin
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Korea.
J Cerebrovasc Endovasc Neurosurg. 2021 Dec;23(4):327-333. doi: 10.7461/jcen.2021.E2021.06.001. Epub 2021 Nov 12.
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating cerebrovascular event; patients are routinely admitted to the intensive care unit (ICU) for initial management. Because complications may be delayed, unplanned ICU readmissions can occur. Therefore, in this study we evaluate the rate of and factors associated with readmission after aSAH and identify if readmission is associated with poor clinical outcomes.
We retrospectively reviewed the medical records of all patients receiving surgical or endovascular treatment for aSAH and admitted to the ICU between January 2008 and December 2019. We categorized patients by readmission and analyzed their clinical parameters.
Of the 345 patients who transferred to ward-level care after an initial ICU stay (Group 2), 27 (7.3%) were readmitted to the ICU (Group 1). History of hypertension (HTN), initial Glasgow Coma Scale (GCS) score, modified Fisher grade, and vasospasm therapy during first ICU stay were significantly different between the groups. The most common reason for readmission was delayed cerebral ischemia (DCI; 70.3%; OR 5.545; 95% CI 1.25-24.52; p=0.024). Comorbid HTN (OR 5.311; 95% CI 1.75-16.12; p=0.03) and vasospasm therapy during first ICU stay (OR 7.234; 95% CI 2.41-21.7; p<0.01) also were associated with readmission. Readmitted patients had longer hospital stay and lower GCS scores at discharge (p<0.01).
DCI was the most common cause of ICU readmission in patients with aSAH. Readmission may indicate clinical deterioration, and patients who are at a high risk for DCI should be monitored to prevent readmission.
动脉瘤性蛛网膜下腔出血(aSAH)是一种严重的脑血管事件;患者通常被收入重症监护病房(ICU)进行初始治疗。由于并发症可能延迟出现,可能会发生计划外的ICU再入院情况。因此,在本研究中,我们评估了aSAH后再入院的发生率及相关因素,并确定再入院是否与不良临床结局相关。
我们回顾性分析了2008年1月至2019年12月期间因aSAH接受手术或血管内治疗并入住ICU的所有患者的病历。我们按再入院情况对患者进行分类,并分析他们的临床参数。
在最初入住ICU后转至病房护理的345例患者(第2组)中,27例(7.3%)再次入住ICU(第1组)。两组患者的高血压(HTN)病史、初始格拉斯哥昏迷量表(GCS)评分、改良Fisher分级以及首次入住ICU期间的血管痉挛治疗情况存在显著差异。再入院的最常见原因是迟发性脑缺血(DCI;70.3%;比值比5.545;95%置信区间1.25 - 24.52;p = 0.024)。合并HTN(比值比5.311;95%置信区间1.75 - 16.12;p = 0.03)以及首次入住ICU期间的血管痉挛治疗(比值比7.234;95%置信区间2.41 - 21.7;p<0.01)也与再入院相关。再入院患者的住院时间更长,出院时GCS评分更低(p<0.01)。
DCI是aSAH患者ICU再入院的最常见原因。再入院可能表明临床病情恶化,应对有DCI高风险的患者进行监测以预防再入院。